Patenting Human Genes in Europe: and how it compares to the US and Australia

Publikation: Bidrag til bog/antologi/rapportBidrag til bog/antologiForskningfagfællebedømt

In accordance with the concept of the book and the assigned scope of the contribution, this chapter describes the European law with respect to the patent-eligibility of isolated DNA sequences. This chapter will further include a brief comparison with recent developments from the US and Australia. It will, however, not focus on the important debates regarding the patent-eligibility of other biological material, diagnostic methods patents (as data aggregators) or abstract ideas which will be addressed by other contributions. Moreover, the analysis will merely concentrate on patent-eligibility. Other patentability requirement will only be briefly touched upon in the discussion part.

The paper starts out in section 1.5.2 by discussing the patent-eligibility of isolated human DNA sequences on the European national level and under the Biotechnology Directive. Then the patent-eligibility of isolated human DNA sequences at the EPO will be analyzed in section 1.5.3. This will provide the basis for the final section 1.5.4, which provides a brief discussion and some concluding remarks on the current European approaches and about what effect might the recent U.S. and Australian developments might have on European policy debates and legislation.
OriginalsprogEngelsk
TitelResearch Handbook on Intellectual Property and the Life Sciences
RedaktørerDuncan Matthews, Herbert Zech
Antal sider14
Udgivelses stedCheltenham
ForlagEdward Elgar Publishing
Publikationsdatojul. 2017
Sider26-39
KapitelPart I, Chapter 3
ISBN (Trykt)9781783479442
ISBN (Elektronisk) 9781783479450
DOI
StatusUdgivet - jul. 2017
NavnResearch Handbooks in Intellectual Property series

ID: 138858996